Antidepressants Strongly Influence the Relationship Between Depression
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Endogenous Metabolites in Drug Discovery: from Plants to Humans
Endogenous Metabolites in Drug Discovery: from Plants to Humans Joaquim Olivés Farrés TESI DOCTORAL UPF / ANY 201 6 DIRECTOR DE LA TESI: Dr. Jordi Mestres CEXS Department The research in this T hesis has been carried out at the Systems Pharmacolo gy Group , within the Research Programme on Biomedical Informatics (GRIB) at the Parc de Recerca Biomèdica de Barcelona (PRBB). The research presented in this T hesis has been supported by Ministerio de Ciencia e Innovación project BIO2014 - 54404 - R and BIO2011 - 26669 . Printing funded by the Fundació IMIM’s program “Convocatòria d'ajuts 2016 per a la finalització de tesis doctorals de la Fundació IMIM.” Agraïments Voldria donar les gràcies a tanta gent que em fa por deixar - me ningú. Però per c omençar haig agrair en especial al meu director la tesi, Jordi Mestres, per donar - me la oportunitat de formar part del seu laboratori i poder desenvolupar aquí el treball que aquí es presenta. A més d’oferir l’ajuda necessària sempre que ha calgut. També haig de donar les gràcies a tots els companys del grup de Farmacologia de Sistemes que he anat coneguent durants tots aquests anys en què he estat aquí, en especial en Xavi, a qui li he preguntat mil coses, en Nikita, pels sdfs que m’ha anat llençant a CTL ink, i la Irene i la Cristina, que els seus treballs també m’ajuden a completar la tesis. I cal agrair també a la resta de companys del laboratori, l’Albert, la Viktoria, la Mari Carmen, l’Andreas, en George, l’Eric i l’Andreu; de Chemotargets, en Ricard i en David; i altres membres del GRIB, com són l’Alfons, en Miguel, en Pau, l’Oriol i la Carina. -
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole -
Summary of Product Characteristics 1. Name Of
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Molterfin 2 mg sublingual tablets. Molterfin 8 mg sublingual tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg sublingual tablets: Each sublingual tablet contains buprenorphine hydrochloride corresponding to 2 mg buprenorphine. 8 mg sublingual tablets: Each sublingual tablet contains buprenorphine hydrochloride corresponding to 8 mg buprenorphine. Excipient(s) with known effect: 2 mg sublingual tablets: Lactose 48 mg. 8 mg sublingual tablets: Lactose 191 mg. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Sublingual Tablet Appearance: 2 mg tablets: Oval, biconvex, white tablets with ”2” embossed on one side. 8 mg tablets: Oval, biconvex, white tablets with ”8” embossed on one side. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. 4.2 Posology and method of administration Posology Adults: Treatment with Molterfin sublingual tablets is intended for use in adults who have agreed to be treated for addiction to opioids. Treatment must be under the supervision of a physician experienced in the management of opiate dependence/addiction. When treatment with Molterfin is initiated, the physician should be aware of the partial agonist profile of the buprenorphine molecule. Buprenorphine binds to and opioid receptors and may trigger withdrawal symptoms in opioid-dependent patients. 1 Induction therapy: The initial dose is 0.8 to 4 mg administered as a single daily dose. In case an initial dose below 2 mg is required, another medicinal product of buprenorphine sublingual tablets should be used for that strength, since Molterfin is available only as 2 mg and 8 mg dose strength. -
Journal of Public Health Research
Journal of Public Health Research eISSN 2279-9036 https://www.jphres.org/ Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Journal of Public Health Research is, therefore, E-publishing PDF files of an early version of manuscripts that undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors. J Public Health Res 2021 [Online ahead of print] To cite this Article: Mitkova Z, Kamusheva M, Kalpachka D, et al. Review of medicine utilization for Parkinson’s disease management: the Bulgarian perspective. doi: 10.4081/jphr.2021.2396 © the Author(s), 2021 Licensee PAGEPress, Italy Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article. Review of medicine utilization for Parkinson’s disease management: the Bulgarian perspective Zornitsa Mitkova1, Maria Kamusheva1, Dobrinka Kalpachka2,, Desislava Ignatova3, Konstantin Tachkov1and Guenka Petrova1 1Department of Organisation and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia 2Department of Neurology, “Saint Anna” Hospital, Sofia 3Department of Psychiatry and Medical Psychology, Medical University of Sofia, Bulgaria Correspondence: Zornitsa Mitkova; Medical University of Sofia, Faculty of Pharmacy, Department of Organisation and Economy of Pharmacy, Dounavstr2;Sofia 1000, Bulgaria;Tel.: +359888 535759 ; e-mail: [email protected]; Significance for public health Parkinson’s disease is the second most common neurodegenerative disorder affecting high number of the population. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open: first published as 10.1136/bmjopen-2019-029221 on 4 September 2019. Downloaded from http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected by copyright. responses online. online. responses ). ). http://bmjopen.bmj.com email please process review peer open BMJ Open’s on any questions If you have [email protected] BMJ Open is committed to open peer review. As part of this commitment we make the peer review review peer the make we commitment of this As part review. open peer to committed is Open BMJ available. publicly publish we article every of history authors’ the and comments reviewers’ the peer we post published is an article When that versions the are These peer review. during used were that paper of the versions the post We also to. apply comments review the peer review the peer during submitted that were versions the are follow that paper of the The versions or cited be not should They versions. published final or the of record versions the not are They process. manuscript. of this version published as the distributed of of record version author-corrected and typeset final, the full, journal and open access an is Open BMJ fees pay-per-view or charges subscription controls, access with no site on our available is manuscript the ( BMJ Open BMJ Open: first published as 10.1136/bmjopen-2019-029221 on 4 September 2019. Downloaded from An analysis of anticholinergic and sedative medicine effects on medicine-induced deterioration and frailty: a cross- sectional study ForJournal: peerBMJ Open review only Manuscript -
Estonian Statistics on Medicines 2013 1/44
Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P) -
Analysis of Anticholinergic and Sedative Medicine Effects on Physical Function, Cognitive Function, Appetite and Frailty: a Cross-Sectional Study in Australia
Open access Original research BMJ Open: first published as 10.1136/bmjopen-2019-029221 on 4 September 2019. Downloaded from Analysis of anticholinergic and sedative medicine effects on physical function, cognitive function, appetite and frailty: a cross-sectional study in Australia Renly Lim, Lisa M Kalisch Ellett, Imaina S Widagdo, Nicole L Pratt, Elizabeth Ellen Roughead To cite: Lim R, Kalisch ABSTRACT Strengths and limitations of this study Ellett LM, Widagdo IS, et al. Objective To test the association between use of Analysis of anticholinergic medicines with anticholinergic or sedative properties and ► Our findings on the association between use of anti- and sedative medicine physical function, cognitive function, appetite and frailty. effects on physical function, cholinergics and poorer appetite contribute uniquely Design, setting and participants This cross-sectional cognitive function, appetite to the literature. study analysed baseline data collected as part of the and frailty: a cross-sectional ► We analysed the association between medicines Australian Longitudinal Study of Ageing, a population- study in Australia. BMJ Open with anticholinergic or sedative properties and grip based cohort of 2087 participants aged 65 years or over 2019;9:e029221. doi:10.1136/ strength based on sex, which previous studies have living in South Australia. bmjopen-2019-029221 not done. Main outcome measures Physical function was ► Prepublication history for ► The outcome measures chosen were both objective measured at baseline using measures including hand grip this paper is available online. and clinically relevant. strength, walking speed, chair stands, activities of daily To view these files, please visit ► The study is limited by its cross-sectional design. -
An Anticholinergic Burden Score for German Prescribers: Score Development Esther Katharina Kiesel1* , Yvonne Marina Hopf1 and Michael Drey2
Kiesel et al. BMC Geriatrics (2018) 18:239 https://doi.org/10.1186/s12877-018-0929-6 RESEARCH ARTICLE Open Access An anticholinergic burden score for German prescribers: score development Esther Katharina Kiesel1* , Yvonne Marina Hopf1 and Michael Drey2 Abstract Background: Anticholinergic drugs put elderly patients at a higher risk for falls, cognitive decline, and delirium as well as peripheral adverse reactions like dry mouth or constipation. Prescribers are often unaware of the drug- based anticholinergic burden (ACB) of their patients. This study aimed to develop an anticholinergic burden score for drugs licensed in Germany to be used by clinicians at prescribing level. Methods: A systematic literature search in pubmed assessed previously published ACB tools. Quantitative grading scores were extracted, reduced to drugs available in Germany, and reevaluated by expert discussion. Drugs were scored as having no, weak, moderate, or strong anticholinergic effects. Further drugs were identified in clinical routine and included as well. Results: The literature search identified 692 different drugs, with 548 drugs available in Germany. After exclusion of drugs due to no systemic effect or scoring of drug combinations (n = 67) and evaluation of 26 additional identified drugs in clinical routine, 504 drugs were scored. Of those, 356 drugs were categorised as having no, 104 drugs were scored as weak, 18 as moderate and 29 as having strong anticholinergic effects. Conclusions: The newly created ACB score for drugs authorized in Germany can be used in daily clinical practice to reduce potentially inappropriate medications for elderly patients. Further clinical studies investigating its effect on reducing anticholinergic side effects are necessary for validation. -
The Selection and Use of Essential Medicines
WHO Technical Report Series 958 THE SELECTION AND USE OF ESSENTIAL MEDICINES This report presents the recommendations of the WHO Expert THE SELECTION AND USE Committee responsible for updating the WHO Model List of Essential Medicines. The fi rst part contains a review of the OF ESSENTIAL MEDICINES report of the meeting of the Expert Subcommittee on the Selection and Use of Essential Medicines, held in October 2008. It also provides details of new applications for paediatric medicines and summarizes the Committee’s considerations and justifi cations for additions and changes to the Model List, including its recommendations. Part Two of the publication is the report of the second meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. Annexes include the revised version of the WHO Model List of Essential Medicines (the 16th) and the revised version of the WHO Model List of Report of the WHO Expert Committee, 2009 Essential Medicines for Children (the 2nd). In addition there is a list of all the items on the Model List sorted according to their (including the 16th WHO Model List of Essential Medicines Anatomical Therapeutic Chemical (ATC) classifi cation codes. and the 2nd WHO Model List of Essential Medicines for Children) WHO Technical Report Series — 958 WHO Technical ISBN 978-92-4-120958-8 Geneva TTRS958cover.inddRS958cover.indd 1 110.06.100.06.10 008:328:32 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open: first published as 10.1136/bmjopen-2020-039747 on 22 October 2020. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-039747 on 22 October 2020. Downloaded from Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-039747 Article Type: Original research Date Submitted by the 24-Apr-2020 -
Review of Existing Classification Efforts
Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.